| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0959-8049(97)00364-X |
| P698 | PubMed publication ID | 9713264 |
| P50 | author | Thierry André | Q56250413 |
| P2093 | author name string | C Louvet | |
| A de Gramont | |||
| M Krulik | |||
| C Tournigand | |||
| P2860 | cites work | Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data | Q31145605 |
| Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer | Q33499176 | ||
| Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma | Q38207042 | ||
| Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer | Q39488860 | ||
| Fluorouracil: biochemistry and pharmacology | Q39527807 | ||
| Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells | Q41511850 | ||
| A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer | Q41999978 | ||
| The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group | Q43427611 | ||
| A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma | Q43967077 | ||
| A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study | Q44583571 | ||
| Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study | Q44664927 | ||
| Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid | Q45019544 | ||
| Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy | Q47577784 | ||
| Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer | Q68043719 | ||
| Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project | Q68056139 | ||
| High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer | Q68098925 | ||
| 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group Study | Q68929606 | ||
| A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma | Q70222887 | ||
| Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer | Q71072643 | ||
| Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU | Q71079673 | ||
| Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study | Q73117412 | ||
| Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD) | Q73155409 | ||
| Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD) | Q73155411 | ||
| Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines | Q73177853 | ||
| P433 | issue | 5 | |
| P921 | main subject | colorectal cancer | Q188874 |
| fluorouracil | Q238512 | ||
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 619-626 | |
| P577 | publication date | 1998-04-01 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD) | |
| P478 | volume | 34 |
| Q36397352 | Activity of boanmycin against colorectal cancer |
| Q73409052 | CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR |
| Q34099447 | Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells |
| Q36960766 | Current and emerging trends in the treatment of early-stage colorectal cancer: importance of a multidisciplinary approach |
| Q37570370 | Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients? |
| Q33634975 | ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy |
| Q35097975 | Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer |
| Q60957206 | Enhanced Anticancer Activity of 5'-DFUR-PCL-MPEG Polymeric Prodrug Micelles Encapsulating Chemotherapeutic Drugs |
| Q78304355 | European School of Oncology--inside track conference: colorectal cancer |
| Q43516115 | Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). |
| Q44734913 | Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression |
| Q33337184 | High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). |
| Q46921743 | New drug formulations for cancer therapy |
| Q44938504 | Oxaliplatin added to simplified bimonthly low-dose leucovorin and 5-FU for pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens |
| Q33331373 | Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. |
| Q34086049 | Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies |
| Q43658197 | Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer |
| Q36692398 | Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer |
| Q36621545 | Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil |
| Q34648284 | Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer |
| Q33599123 | Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis |
| Q74283605 | The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine |
| Q38097808 | The evolving role of oxaliplatin in the management of colorectal cancer. |
| Q34211250 | The oral fluorinated pyrimidines |
| Q33360849 | Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract |
Search more.